Registry update — unassessed
(MATE) Metformin and Aging Trial in the Elderly: A Pilot and Feasibility Study
Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Nov 17, 2022 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No effect sizes or outcome data were reported, so efficacy of metformin on any measured parameter cannot be assessed from this abstract. This is a pilot/feasibility study, which typically prioritizes recruitment and protocol adherence rather than demonstrating clinical benefit. As a pilot study, results cannot be generalized or used to establish whether metformin affects longevity or aging biomarkers in elderly populations.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Elderly
- Primary outcome
- Physical performance as measured by short physical performance battery test
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Nov 17, 2022
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.